[HTML][HTML] Biomarker analyses and overall survival (OS) from the randomized, placebo-controlled, phase 3, FASTACT-2 study of intercalated erlotinib with first-line …
TSK Mok, JS Lee, L Zhang, C Yu, S Thongprasert… - Annals of …, 2012 - Elsevier
Background FASTACT-2 is a randomized, placebo-controlled, phase 3 study in first-line
advanced NSCLC, which met its primary endpoint of significantly prolonged PFS with …
advanced NSCLC, which met its primary endpoint of significantly prolonged PFS with …
Biomarker Analyses and Overall Survival (OS) from the Randomized, Placebo-Controlled, Phase 3, Fastact-2 Study of Intercalated Erlotinib with First-Line …
TSK Mok, JS Lee, L Zhang, C Yu… - Annals of …, 2012 - annalsofoncology.org
Background FASTACT-2 is a randomized, placebo-controlled, phase 3 study in first-line
advanced NSCLC, which met its primary endpoint of significantly prolonged PFS with …
advanced NSCLC, which met its primary endpoint of significantly prolonged PFS with …